PL369141A1 - Kompozycje zawierające epotylony i ich zastosowanie do leczenia zespołu rakowiaka - Google Patents
Kompozycje zawierające epotylony i ich zastosowanie do leczenia zespołu rakowiakaInfo
- Publication number
- PL369141A1 PL369141A1 PL02369141A PL36914102A PL369141A1 PL 369141 A1 PL369141 A1 PL 369141A1 PL 02369141 A PL02369141 A PL 02369141A PL 36914102 A PL36914102 A PL 36914102A PL 369141 A1 PL369141 A1 PL 369141A1
- Authority
- PL
- Poland
- Prior art keywords
- carcinoid syndrome
- combination
- treatment
- epothilones
- compositions
- Prior art date
Links
- 206010007270 Carcinoid syndrome Diseases 0.000 title abstract 3
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 abstract 2
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001142 anti-diarrhea Effects 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 229960001052 streptozocin Drugs 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34216701P | 2001-12-13 | 2001-12-13 | |
| US41599002P | 2002-10-04 | 2002-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL369141A1 true PL369141A1 (pl) | 2005-04-18 |
| PL209147B1 PL209147B1 (pl) | 2011-07-29 |
Family
ID=26992855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL369141A PL209147B1 (pl) | 2001-12-13 | 2002-12-12 | Zastosowanie epotylonów do wytwarzania środka leczniczego do leczenia zespołu rakowiaka i/lub co najmniej jednego guza neuroendokrynnego |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20050020647A1 (pl) |
| EP (1) | EP1463504B1 (pl) |
| JP (1) | JP4672257B2 (pl) |
| KR (1) | KR101010767B1 (pl) |
| CN (1) | CN1602192A (pl) |
| AT (1) | ATE330602T1 (pl) |
| BR (1) | BR0214917A (pl) |
| CA (1) | CA2468994A1 (pl) |
| CY (1) | CY1105459T1 (pl) |
| DE (1) | DE60212710T2 (pl) |
| DK (1) | DK1463504T3 (pl) |
| ES (1) | ES2266610T3 (pl) |
| HU (1) | HUP0402537A3 (pl) |
| IL (1) | IL162166A0 (pl) |
| MX (1) | MXPA04005712A (pl) |
| NO (1) | NO332773B1 (pl) |
| NZ (1) | NZ533378A (pl) |
| PL (1) | PL209147B1 (pl) |
| PT (1) | PT1463504E (pl) |
| RU (1) | RU2341261C2 (pl) |
| TW (1) | TWI287986B (pl) |
| WO (1) | WO2003049734A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| RU2346686C2 (ru) * | 2002-01-14 | 2009-02-20 | Новартис Аг | Комбинации, включающие эпотилоны и антиметаболиты |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| JP2006504745A (ja) * | 2002-10-09 | 2006-02-09 | コーザン バイオサイエンシス インコーポレイテッド | エポｄ及び５−ｆｕ／ゲムシタビン |
| US20060235059A1 (en) * | 2003-09-02 | 2006-10-19 | Dilea Clifford | Cancer treatment with epothilones |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| CN103037903A (zh) | 2010-05-18 | 2013-04-10 | 天蓝制药公司 | 用于治疗自身免疫性疾病或其它疾病的组合物和方法 |
| PL3253401T3 (pl) | 2015-02-03 | 2025-08-04 | Amryt Endo, Inc. | Leczenie akromegalii oktreotydem doustnym |
| RU2633266C2 (ru) * | 2015-07-02 | 2017-10-11 | Рауф Ашрафович Ашрафов | Способ моделирования карциноидного синдрома |
| EP4482491A4 (en) * | 2022-02-25 | 2026-02-25 | Amryt Endo Inc | ORAL OCTREOTIDE FOR THE TREATMENT OF A DISEASE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356270A (en) * | 1977-11-08 | 1982-10-26 | Genentech, Inc. | Recombinant DNA cloning vehicle |
| US4318477A (en) * | 1980-09-22 | 1982-03-09 | Kerpe Stase Z | Pharmaceutical package |
| US5753616A (en) * | 1986-11-10 | 1998-05-19 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| DE3822557C2 (de) * | 1987-07-10 | 1998-07-02 | Ciba Geigy Ag | Arzneimittel, enthaltend Somatostatine |
| ES2248847T3 (es) * | 1996-05-24 | 2006-03-16 | Angiotech Pharmaceuticals, Inc. | Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo. |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| JP4274583B2 (ja) * | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤 |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| WO2001092255A2 (en) * | 2000-05-26 | 2001-12-06 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
-
2002
- 2002-12-11 TW TW091135843A patent/TWI287986B/zh not_active IP Right Cessation
- 2002-12-12 IL IL16216602A patent/IL162166A0/xx unknown
- 2002-12-12 WO PCT/EP2002/014162 patent/WO2003049734A1/en not_active Ceased
- 2002-12-12 AT AT02790487T patent/ATE330602T1/de active
- 2002-12-12 EP EP02790487A patent/EP1463504B1/en not_active Expired - Lifetime
- 2002-12-12 CA CA002468994A patent/CA2468994A1/en not_active Abandoned
- 2002-12-12 CN CNA028248341A patent/CN1602192A/zh active Pending
- 2002-12-12 JP JP2003550783A patent/JP4672257B2/ja not_active Expired - Fee Related
- 2002-12-12 DE DE60212710T patent/DE60212710T2/de not_active Expired - Lifetime
- 2002-12-12 HU HU0402537A patent/HUP0402537A3/hu unknown
- 2002-12-12 BR BR0214917-6A patent/BR0214917A/pt not_active IP Right Cessation
- 2002-12-12 US US10/498,069 patent/US20050020647A1/en not_active Abandoned
- 2002-12-12 ES ES02790487T patent/ES2266610T3/es not_active Expired - Lifetime
- 2002-12-12 KR KR1020047009001A patent/KR101010767B1/ko not_active Expired - Fee Related
- 2002-12-12 NZ NZ533378A patent/NZ533378A/xx not_active IP Right Cessation
- 2002-12-12 RU RU2004121687/15A patent/RU2341261C2/ru not_active IP Right Cessation
- 2002-12-12 DK DK02790487T patent/DK1463504T3/da active
- 2002-12-12 PL PL369141A patent/PL209147B1/pl not_active IP Right Cessation
- 2002-12-12 MX MXPA04005712A patent/MXPA04005712A/es active IP Right Grant
- 2002-12-12 PT PT02790487T patent/PT1463504E/pt unknown
-
2004
- 2004-07-05 NO NO20042832A patent/NO332773B1/no not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/451,286 patent/US20060229345A1/en not_active Abandoned
- 2006-09-07 CY CY20061101280T patent/CY1105459T1/el unknown
-
2009
- 2009-05-07 US US12/437,226 patent/US20090246172A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162166A0 (en) | Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome | |
| SI2017276T1 (sl) | Fenil-karboksamidne spojine, uporabne za tretiranje bolečine | |
| WO2001072721A3 (en) | Synergistic methods and compositions for treating cancer | |
| IL143388A0 (en) | Compositions and methods for stimulating gastrointestinal motility | |
| FR2762843B1 (fr) | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| WO2003004098A8 (en) | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent | |
| EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| JP2003522198A5 (pl) | ||
| YU53402A (sh) | Preparat | |
| CL2004001050A1 (es) | Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul | |
| WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
| PL342614A1 (en) | Anticarcinogenic drugs | |
| EP1184035A3 (en) | Use of growth hormone secretagogues for treatment of physical performance decline | |
| WO2003007924A3 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| EP2030618A3 (en) | Combinations comprising epothilones and anti-metabolites | |
| CA2501610A1 (en) | Epothilone derivatives for the treatment of multiple myeloma | |
| WO2002040477A3 (en) | Saframycins, analogues and uses thereof | |
| WO2006031719A3 (en) | 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof | |
| UA85199C2 (ru) | Применение циклических пептидов типа анабенопептина для лечения состояний, при которых показано угнетение карбоксипептидазы u, производные анабенопептина и их промежуточные соединения | |
| CA2478223A1 (en) | Combinations comprising epothilone derivatives and alkylating agents | |
| CA2501717A1 (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| WO2001030328A3 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten | |
| RU2004116067A (ru) | Фармацевтические композиции, содержащие макролиды | |
| UA74406C2 (uk) | Полісахаридна сполука з імуностимулювальною активністю, спосіб її одержання, застосування та фармацевтичний препарат на її основі | |
| MXPA05003633A (es) | 2"-oxo-voruscharina y derivados de la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20131212 |